Compare Abbott Laboratories (ABT) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Boston Beer Company Inc — how do they compare? Abbott Laboratories trades at $95.38 (market cap $166.94B), while Boston Beer Company Inc trades at $180.14 (market cap $1.91B). The key difference: Abbott Laboratories is far larger — about 87.4× Boston Beer Company Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| ABT | SAM | |
|---|---|---|
Market Cap | $166.94B | $1.91B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $260.05 |
52-Week Low | $82.57 | $161.08 |
Enterprise Value | $193.69B | $1.78B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Boston Beer (SAM) trades at $183.16, down 0.25% with bearish technical signals. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but negative net income margin of -3.15% and ROE of -7.75%. Recent Q1 2026 earnings missed expectations, though Q3 and Q4 2025 beat estimates. Cash flow improved to $11.56M net in 2025 after a negative 2024. Analyst consensus price target is $233.40 with 74% hold ratings.
SAM faces headwinds from declining volume growth and brand pressure, but maintains strong gross margins at 48.7%. The 27% upside to consensus target offers potential, though execution risks and competitive beverage market pose challenges. Institutional sentiment is cautious with limited buy ratings despite positive cash flow recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
